

Description générale

Cytarabine is a pyrimidine nucleoside analogue antineoplastic agent used in the treatment of leukaemias and lymphomas.

INN	Cytarabine
Codes ATC	L01BC01
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 1979 (TRS 641) pour Lymphoid leukaemia, not elsewhere classified Ajouté en 1979 (TRS 641) pour Myeloid leukaemia Ajouté en 1979 (TRS 641) pour Acute myeloid leukaemia with recurrent genetic abnormalities Ajouté en 1979 (TRS 641) pour Burkitt lymphoma including Burkitt leukaemia Ajouté en 1979 (TRS 641) pour Unspecified malignant neoplasms of ill-defined or unspecified sites Retiré en 2015 (TRS 994) pour Unspecified malignant neoplasms of ill-defined or unspecified sites Ajouté en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-positive Ajouté en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-negative Ajouté en 2023 (TRS 1049) pour Langerhans cell histiocytosis
Wikipédia	Cytarabine 
DrugBank	Cytarabine 

Recommandations

Section Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Indications

- Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia
- Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative
- Langerhans cell histiocytosis

